BioAge Labs Shares Jump 14% as Oral NLRP3 Inhibitor Enters Phase 2 for Cardiovascular Risk in Obesity
BioAge Labs (NASDAQ: BIOA) saw its stock rally 14.2% after announcing the first patient dosed in QUELL-CV, a 12-week, 160-patient Phase 2 proof-of-concept trial evaluating its oral NLRP3 inhibitor, BGE-102. The study targets adults with obesity, elevated inflammatory markers, and at least one additional cardiovascular risk factor — a population where chronic inflammation is increasingly recognized as a key driver of adverse outcomes.
What makes BGE-102 stand out is its origin in BioAge’s proprietary human aging data platform. By analyzing large-scale longitudinal cohorts, the company identified a link between lower NLRP3 activity and greater longevity, positioning the drug at the intersection of aging biology and cardiovascular medicine. This mechanistic foundation gives QUELL-CV a distinct scientific narrative, though the trial itself remains a high-risk, binary event for the stock.
BioAge is still a pre-revenue, early-stage biotechnology company. It recently raised roughly $115 million and is projected to remain unprofitable for the foreseeable future. The company’s near-term catalysts now center on BGE-102 results from this cardiovascular trial and an upcoming study in diabetic macular edema (DME). On the flip side, clinical failure, further dilution, and a reversal of speculative momentum remain the most immediate risks.
Valuation estimates for BioAge vary widely. Two Simply Wall St community models place fair value anywhere from about $50 to over $200 per share, reflecting deep disagreement about the probability of commercial success. Against that backdrop, the binary proof-of-concept nature of QUELL-CV means investors should weigh multiple scenarios before anchoring on any single price target. The next major data readout is expected in the second half of 2026.
This article is for general informational purposes only and does not constitute investment advice. It reflects historical data and analyst forecasts using an unbiased methodology. Simply Wall St has no position in any stocks mentioned.